LYRA · As filed with the SEC
Lyra Therapeutics cash flow statement, by quarter
The statement as Lyra Therapeutics presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
Consolidated Statements of Cash Flows · USD
| USD | Q4 2025 3 months ended Dec 31, 2025 | Q3 2025 3 months ended Sep 30, 2025 | Q2 2025 3 months ended Jun 30, 2025 | Q1 2025 3 months ended Mar 31, 2024 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Net loss | — | — | — | (22,452,000) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||||
| Stock-based compensation | — | — | — | 2,162,000 |
| Depreciation expense | — | — | — | 136,000 |
| Net amortization of discount on short-term investments | — | — | — | (933,000) |
| Changes in operating assets and liabilities | ||||
| Prepaid expenses and other current assets | — | — | — | (257,000) |
| Operating lease right-of-use assets | — | — | — | (824,000) |
| Other assets | — | — | — | 568,000 |
| Accounts payable | — | — | — | (560,000) |
| Accrued expenses and other current liabilities | — | — | — | 827,000 |
| Operating lease liabilities | — | — | — | (590,000) |
| Deferred revenue | — | — | — | (532,000) |
| Net cash used in operating activities | — | — | — | (22,455,000) |
| Cash flows from investing activities: | ||||
| Purchases of property and equipment | — | — | — | (2,149,000) |
| Purchases of short-term investments | — | — | — | (20,525,000) |
| Maturity of short-term investments | — | — | — | 30,531,000 |
| Net cash (used in) provided by investing activities | — | — | — | 7,857,000 |
| Cash flows from financing activities: | ||||
| Proceeds from sale of common stock, purchase warrants and pre-funded warrants | — | — | — | 8,810,000 |
| Payment of deferred offering costs | — | — | — | (169,000) |
| Proceeds from exercise of stock options | — | — | — | 3,000 |
| Net cash provided by financing activities | — | — | — | 8,644,000 |
| Net (decrease) increase in cash, cash equivalents and restricted cash | — | — | — | (5,954,000) |
| Cash, cash equivalents and restricted cash, beginning of period | 24,048,000 | 31,777,000 | 17,791,000 | 23,745,000 |
| Cash, cash equivalents and restricted cash, end of period | 17,886,000 | 24,048,000 | 31,777,000 | 17,791,000 |
| Supplemental disclosure of non-cash financing and investing activities: | ||||
| Property and equipment purchases included in accounts payable and accrued expenses | — | — | — | 350,000 |
| Prepaid expenses for right-of-use asset included in operating lease liabilities | — | — | — | 688,000 |
| Deferred offering costs included in accounts payable and accrued expenses | — | — | — | 121,000 |
| Right of Use Asset in Exchange for Lease Liability | — | — | — | 13,667,000 |
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.